An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors

Trial Profile

An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Oxaliplatin; Vanucizumab
  • Indications Gastric cancer; Liver cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 15 Feb 2017 Protocol was amended to changed the treatment arms from 2 to 5 and addition of two new drugs vanucizumab ,cisplatin .
    • 10 Feb 2017 Planned number of patients changed from 60 to 291.
    • 10 Feb 2017 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top